Binimetinib (MEK162)

Synonyms: ARRY-162,ARRY-438162

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.

Binimetinib (MEK162) Chemical Structure

Binimetinib (MEK162) Chemical Structure

CAS: 606143-89-9

Selleck's Binimetinib (MEK162) has been cited by 90 publications

Purity & Quality Control

Batch: Purity: 99.98%
99.98

Products often used together with Binimetinib (MEK162)

Trametinib (GSK1120212)


Binimetinib and Trametinib subcutaneous injection result in hypopigmentation and almost complete loss of melanocytes.

Choi YS, et al. Cell. 2022 Jun 9;185(12):2071-2085.e12.

Cobimetinib (GDC-0973)


Binimetinib and Cobimetinib are MEK 1 inhibitors that are FDA-approved together with RAF inhibitors to treat BRAF V600 mutant melanoma.

Gao Y, et al. Cancer Discov. 2019 Sep;9(9):1182-1191.

Encorafenib


Binimetinib and Encorafenib is the third BRAF plus MEK inhibitor combination to be approved.

Davis J, et al. J Adv Pract Oncol. 2022 May;13(4):450-455.

Selumetinib (AZD6244)


Selumetinib is the only licensed medical therapy for NF1-PN pediatric patients, whereas binimetinib is being investigated as a medical therapy for NF1-PN.

Armstrong AE, et al. BMC Cancer. 2023 Jun 16;23(1):553.

Binimetinib (MEK162) Related Products

Signaling Pathway

Choose Selective MEK Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H727 Function assay IC50=115 nM 30352565
Mel IL Cytotoxicity assay IC50=3.7 ± 0.2 μM 30551515
Mel IL/R Cytotoxicity assay IC50=2.7 ± 0.3 μM 30551515
Mel Z Cytotoxicity assay IC50=3.8 ± 0.2 μM 30551515
A375 Cytotoxicity assay IC50=9.8 ± 0.1 μM 30551515
Mel Me Cytotoxicity assay IC50=13.3 ± 0.3 μM 30551515
Mel MTP Cytotoxicity assay IC50=10.2 ± 0.4 μM 30551515
U2OS cells Function assay 1 μM MEK162 blocked ERK activation (p-ERK1/2) in CZ415-treated U2OS cells 29137241
CHP-212 Cell viability assay 120 h IC50=0.0083 μM 26925841
SK-N-AS Cell viability assay 120 h IC50=0.067 μM 26925841
SK-N-BE(2) Cell viability assay 120 h IC50=0.28 μM 26925841
SJ-NB-10 Cell viability assay 120 h IC50=1.16 μM 26925841
CHP-134 Cell viability assay 120 h IC50>15 μM 26925841
Kelly Cell viability assay 120 h IC50>15 μM 26925841
LAN-5 Cell viability assay 120 h IC50>15 μM 26925841
NGP Cell viability assay 120 h IC50>15 μM 26925841
SK-N-DZ Cell viability assay 120 h IC50>15 μM 26925841
A549 Cell cycle assay 0, 0.5, 1 μM 48h at relatively low concentration ranges ≤ 1 μM (e.g., 0.5 and 1 μM) induced G1 arrest 25937299
H157 Cell cycle assay 0, 0.5, 1 μM 48h at relatively low concentration ranges ≤ 1 μM (e.g., 0.5 and 1 μM) induced G1 arrest 25937299
H522 Cell cycle assay 0, 0.5, 1 μM 48h at relatively low concentration ranges ≤ 1 μM (e.g., 0.5 and 1 μM) induced G1 arrest 25937299
Click to View More Cell Line Experimental Data

Biological Activity

Description Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Targets
MEK [1]
(Cell-free assay)
12 nM
In vitro
In vitro

ARRY-438162 (625 nM) inhibits in vitro osteoclast differentiation with IC50 of 39 nM. ARRY-438162 (10 μM) inhibits in vitro osteoclast resorption with IC50 of 625 nM. ARRY-438162 (2 μM) weakly affects osteoblast differentiation. [2]

ARRY-438162 is a recently disclosed potent and selective ATP non-competitive MEK1/2 inhibitor, inhibits pERK in cells with an IC50 of11 nM. [3]

MEK162 (1 μM) combined with MK-2206 (2 μM) completely reverses the resistance of RSK-expressing MCF7 cells. [4]

Experimental Result Images Methods Biomarkers Images PMID
Western blot p-KIT / KIT / ETV1 MEK / p-MEK / ERK / p-ERK 25572173
Growth inhibition assay Cell viability 26925841
In Vivo
In vivo

ARRY-438162 (10 mg/kg, po, bid) reduces disease severity in a dose-related manner in rat collagen-induced arthritis (CIA) and rat adjuvant-induced arthritis (AIA) models. ARRY-438162 (po, bid) inhibits increases in ankle diameter by 27% and 50% at 1 mg/kg and 3 mg/kg in the rat collagen-induced arthritis (CIA) model, while ibuprofen has 46% inhibition. ARRY-438162 (10 mg/kg, po, bid) significantly inhibits lesions (inflammation, cartilage damage, pannus formation and bone resorption) by 32% and 60% at 1 mg/kg and 3 mg/kg in the rat collagen-induced arthritis (CIA) model. ARRY-438162 inhibits AIA ankle diameter 11% and 34% at 3 mg/kg and 10 mg/kg in rat adjuvant-induced arthritis (AIA) models. [1]

ARRY-438162 demonstrates dose-related inhibition of ankle swelling in rat adjuvant-induced arthritis (AIA) models, significant at 10 mg/kg and 30 mg/kg when compared to vehicle control. ARRY-438162 demonstrates dose-related inhibition of serum IL-6 concentration in rat adjuvant-induced arthritis (AIA) models, with complete inhibition at 10 mg/kg when compared to vehicle control. ARRY-438162 (30 mg/kg) demonstrates dose-related inhibition of relative spleen weights in rat adjuvant-induced arthritis (AIA) models. ARRY-438162 (30 mg/kg) significantly inhibits bone resorption and inflammation with delayed dosing when compared to vehicle in rat adjuvant-induced arthritis (AIA) models. [2]

MEK162 (6 mg/kg, BID) combined with BEZ235 results in a significant reduction of tumor growth in immunodeficient mice injected with MCF7 cells. [4]

Animal Research Animal Models immunodeficient mice injected with MCF7-RSK4 cells.
Dosages 6 mg/kg
Administration oral
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05286788 Recruiting
Adamantinous Craniopharyngioma|Recurrent Adamantinomatous Craniopharyngioma
Nationwide Children''s Hospital|Children''s Hospital Colorado
April 10 2023 Phase 2
NCT05810740 Completed
Melanoma|BRAF V600 Mutation|Unresectable Melanoma|Metastatic Melanoma
Pierre Fabre Medicament|Biotrial
August 31 2022 Phase 1
NCT05195632 Active not recruiting
Non-Small Cell Lung Cancer
Pierre Fabre Medicament
June 2 2022 Phase 2
NCT05767879 Recruiting
Melanoma Stage III|In-Transit Metastasis of Cutaneous Melanoma
Leiden University Medical Center|Pierre Fabre Laboratories
January 1 2022 Phase 2
NCT05080621 Withdrawn
Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals LLC
November 2021 Phase 1|Phase 2

Chemical Information & Solubility

Molecular Weight 441.23 Formula

C17H15BrF2N4O3

CAS No. 606143-89-9 SDF Download Binimetinib (MEK162) SDF
Smiles CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 88 mg/mL ( (199.44 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Could please clarify the formulation in vivo for S7007 is clear or not?

Answer:
S7007 can be dissolved in 5% DMSO+45% PEG 300+ddH2O at 5 mg/ml clearly for injection.

Tags: buy Binimetinib (MEK162) | Binimetinib (MEK162) supplier | purchase Binimetinib (MEK162) | Binimetinib (MEK162) cost | Binimetinib (MEK162) manufacturer | order Binimetinib (MEK162) | Binimetinib (MEK162) distributor